Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07042945 | MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) | PHASE1 | RECRUITING | 28 | — | — | Jul 9, 2025 | Aug 17, 2026 | May 26, 2026 | 2 | Moldova, Romania |
Percentage of participants with one or more AEs
Percentage of participants who discontinued study medication due to an AE
Time course of plasma HIV-1 RNA viral load decline.
| Arm | Type | Description |
|---|---|---|
| MK-4646 Panel A | EXPERIMENTAL | MK-4646 160 mg every 24 hours (q24h) for 7 days |
| MK-4646 Panel B | EXPERIMENTAL | MK-4646 ≤460 mg q24h for 7 days |
| MK-4646 Panel C | EXPERIMENTAL | MK-4646 ≤460 mg q24h for 7 days |
| MK-4646 Panel D | EXPERIMENTAL | MK-4646 ≤460 mg every 12 hours (q12h) for 7 days |
| Name | Type | Description |
|---|---|---|
| MK-4646 | DRUG | MK-4646 in capsular form administered orally |
Inclusion Criteria: * Other than having HIV-1, is in good health * Is antiretroviral therapy (ART)-naïve * If ART-experienced has not received any antiretroviral therapy within 60 days (or 5 half-lives, whichever is longer) prior to screening * Is willing to receive no other ART prior to Day 8 post...